<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142779">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01705184</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1102</org_study_id>
    <secondary_id>2012-002647-18</secondary_id>
    <nct_id>NCT01705184</nct_id>
  </id_info>
  <brief_title>Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.</brief_title>
  <acronym>BUCiL</acronym>
  <official_title>Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the treatment of non-squamous cell lung cancer is based on chemotherapy with
      platinum eventually associated with bevacizumab. A new treatment begins at progression.

      In colo-rectal metastatic cancer, it was demonstrated that the first-line of treatment could
      be administered according to a stop and go strategy respecting therapeutic breaks between
      sequences of identical treatment. During these therapeutic breaks, a treatment of
      maintenance is possibly better than an absence of treatment. These plans benefit to the
      patients in terms of efficiency but also in terms of toxicity, in particular neurological.

      The question is to know if this strategy is feasible in lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>After 3 cycles</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients receiving 3 cycles of chemotherapy with full-dose platinum in the 2nd sequence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Control rate after the 2nd sequence</measure>
    <time_frame>After 3 cycles</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate after the 1st sequence</measure>
    <time_frame>After 3 cycles</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>During Sequence 2 : at the beginning and after 3 cycles</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Nonsquamous Nonsmall Cell Neoplasm of Lung</condition>
  <arm_group>
    <arm_group_label>BUCiL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --&gt; Sequence 2
Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence</description>
    <arm_group_label>BUCiL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence</description>
    <arm_group_label>BUCiL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.</description>
    <arm_group_label>BUCiL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non squamous non small cell lung cancer histologically or cytologically confirmed
             with no EGFR mutation.

          -  Stage IV NSCLC. Patient with cerebral metastasis are eligible if the metastasis is
             asymptomatic.

          -  Measurable disease (recist criteria)

          -  Age ≥18 years

          -  PS0 or 1

        Exclusion Criteria:

          -  Mixed cancer small cells and non small cells or squamous lung cancer . EGFR mutated
             cancer

          -  History of malignant tumour excepted cervical and basocellular cancer and cancer
             cured for at least 5 years.

          -  Tumor invaded the big vessels or the proximal visible in TDM.

          -  History of adjuvant or neoadjuvant chemotherapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaafar BENNOUNA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Gauducheau - Nantes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avignon - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner HILGERS, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radj GERVAIS, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard ZALCMAN, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick DUMONT, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOLINIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord - Oncologie Multidisciplinaire &amp; Innovations Thérapeutiques</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BARLESI</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaafar BENNOUNA, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <phone>+33.1.56.01.65.31</phone>
      <email>jacques.cadranel@tnn.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Cadranel, pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Lyon Sud (Pneumologie)</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Jean Souquet, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes - CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé LENA, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg - NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisabeth QUOIX, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr</url>
    <description>IFCT website</description>
  </link>
  <reference>
    <citation>Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.</citation>
    <PMID>16421419</PMID>
  </reference>
  <reference>
    <citation>Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16.</citation>
    <PMID>22341744</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 18, 2013</lastchanged_date>
  <firstreceived_date>October 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stop and go</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Non-squamous</keyword>
  <keyword>Bevacizumab</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
